|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG007602820 |
| 003 |
DE-627 |
| 005 |
20230605130713.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210512s2023 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)CTG007602820
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)RPCEC00000361
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)Not applicable
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a Itolizumab Safety and Efficacy Study in Covid 19
|b Safety and efficacy of the anti-CD6 itolizumab monoclonal antibody produced in CHO in the treatment of moderate or severe patients with SARS-CoV-2 pneumonia. (COVID-19)
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 26-03-2021, Last updated: 2023-06-05
|
| 650 |
|
4 |
|a Medical Condition: COVID-19 COVID-19 SARS-CoV-2;Coronavirus Infections;SARS Virus;Coronaviridae Infections;Nidovirales Infections;Betacoronavirus;Severe Acute Respiratory Syndrome ;COVID-19;SARS-CoV-2
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Recruitment Status: Not yet recruiting
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 29. Mai
|
| 773 |
1 |
8 |
|g year:2023
|g day:29
|g month:05
|
| 856 |
4 |
0 |
|u https://rpcec.sld.cu/en/trials/RPCEC00000361-En
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2023
|b 29
|c 05
|
Klinische Studie